Dirk Reyn
Dirk Reyn is a Pharmacist and has an MBA from Handelshogeschool (Antwerpen)/Northwestern University (Kellog’s Chicago/USA).
He is currently Venture Partner at BioQube Ventures (an innovative business model to create biotech companies) and interim CEO of Spectricity , an IMEC spin-off with the smallest spectrometer on the planet. Until end of 2017 he was founding CEO of ETheRNA, a spin-off from the University of Brussels with a breakthrough mRNA based immunotherapy for cancer & infectious diseases. He also vice-chairman of Flandersbio, the organization of Flemish biotech companies and Chairman of Across Health. Dirk has gained commercial experience at Eli Lilly and Janssen-Cilag (Johnson & Johnson), responsible for the international strategic marketing of different products including Prozac, Pariet and Prepulsid. He was one of the people responsible for streamlining JNJ’s e-business and became VP for new business development in Europe. In 2006, Dirk co-founded Movetis NV, a JNJ spin-off for GI assets. As CEO, he was instrumental in raising more than EUR €700 million over four years including an IPO and M&A transaction. Movetis had Resolor (prokinetic) approved in 2009 for chronic constipation and launched in four countries with reimbursement. The same year, the company went public on Euronext and in 2010 was acquired by Shire. Dirk worked two year for Shire as Managing director for the GI business in Europe and then founded Progress Pharma, an asset development company, with a team of experienced managers.
He is married to Kristin and has two children, Michael and Birgit. His hobbies are music (High End Hi-Fi projects), Oldtimer cars (historical rally’s) and swimming/tennis.
Sources